{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-033358","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-07-15T20:10:42+00:00","discovered_at":"2026-07-15T20:12:00.594647+00:00","generated_at":"2026-07-15T20:12:16.782977+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Azitra reports ATR-COSF ex vivo results: 4.4-fold elasticity increase, improved distribution","bullets":["ATR-COSF supernatant with recombinant filaggrin showed increased penetration into stratum granulosum with multiple doses in ex vivo human skin.","Hydrogel with 7.5% w/w supernatant increased skin elasticity 4.4-fold; 0.28% w/w restored elasticity to healthy skin levels.","Safety testing confirmed 2% supernatant formulation is non-irritating and non-corrosive to skin and eyes.","CEO plans to optimize formulations and initiate human study for visible wrinkle reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-033358","json":"https://secwatch.observer/filing/0001493152-26-033358.json","markdown":"https://secwatch.observer/filing/0001493152-26-033358.md","text":"https://secwatch.observer/filing/0001493152-26-033358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/0001493152-26-033358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226033358/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T20:12:16.782977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}